[ad_1]
Agency
MEXICO.-Merkel cell cancer, a rare and very aggressive neoplasm is usually a painless tumor of the skin that develops rapidly, may be the color of the complexion or appear in shades of red, blue or purple.
A new immuno-oncology treatment, providing better control, survival and even healing for patients, depending on the stage of diagnosis, says the Excelsior news portal in its website.
This carcinoma appears more frequently in the face, head or neck and is often confused with herpes or warts. Therefore, if you are experiencing rapid growth, consult a dermatology specialist.
It is an orphan disease and some risk factors could contribute to the development of this tumor, such as: weakened immune system, excessive sun exposure, history of skin cancer, color clear skin (white skin) and age over 50 years.
You may also be interested in: Trapped in traffic? Warning! You could be suffering from obesity
In most cases, it is diagnosed at the age of 75, but it can occur at any age. Preventive measures are as follows: Avoid prolonged exposure to the sun Protect the skin and eyes from the sun and pay particular attention to changes.
The custom that emerged in the 1950s It is not healthy to sunbathe every deck or vacation, as the number of skin cancers increases and, although Merkel's cell is rare, the problem is that she is very aggressive and that her survival is very low, Miguel Álvarez Avitia, medical oncologist at the National Cancer Institute (INCAN),
said that in this institution, a Average case of Merkel cell carcinoma is treated each year.
He also explained that the polyomavirus is an oncovirus that is believed to be responsible for many cases of Merkel cell carcinoma but it is not known how humans acquire this virus.
According to two studies conducted by researchers in the United Kingdom. The drug Avelumab, arrived in Mexico this month, showed that a larger number of patients had a complete response to treatment, with the tumor disappearing, the specialist explained.
He emphasized the fact that it also increases the percentage of patients partial response maintaining the benefit of therapy for longer against chemotherapy.
The procedure is beneficial for both already treated and first-line users, and decreases side effects, so that the rate of discontinuation of toxicity treatment is well below that of patients undergoing chemotherapy.
This immuno-oncological treatment blocks the PD-L1 protein which does not allow the immune system. attack on cancer cells.
[ad_2]
Source link
